Protheragen Expands Rare Blood Disease Research Services with Disease Models and Preclinical Studies
Protheragen provides rare blood disease treatment development, disease model development, and preclinical research services. New York, United States, October 16, 2026 — Rare blood diseases usually have a low prevalence and complex pathophysiological mechanisms. The… Read More »Protheragen Expands Rare Blood Disease Research Services with Disease Models and Preclinical Studies





